Posted by Michael Wonder on 18 Nov 2020
European Commission approves Supemtek (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older
18 November 2020 - Contains three times more antigen than standard-dose vaccines.
The European Commission has granted a marketing authorisation for Supemtek, a quadrivalent (four-strain) recombinant influenza vaccine, for the prevention of influenza in adults aged 18 years and older.
Supemtek is the first and only recombinant influenza vaccine now approved in the European Union.
